Among these key inflammatory mediators, interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-α), and high-sensitivity C-reactive protein (hsCRP) are well-established biomarkers of systemic inflammation implicated in both metabolic disorders and cardiovascular disease, as well as in the progression of chronic liver disease [6,7]. This evidence concerns the gene IL6 and metabolic disease.